ArticleJournal of diabetes research2026
In Vivo Evaluation of a Novel Long-Term Intravascular Implantable Continuous Blood Glucose Monitor in an Ovine Model: A Glucotrack Inc. Investigation.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In Vivo Evaluation of a Novel Long-Term Intravascular Implantable Continuous Blood Glucose Monitor in an Ovine Model: A Glucotrack Inc. Investigation.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Implantable intravascular continuous blood glucose monitors (CBGMs) offer a promising approach for accurately measuring glucose levels with short lag times and improved reliability when compared with conventional laboratory-based point-of-care or handheld glucometers. In this study, 34 Glucotrack long-term intravascular CBGM devices were implanted into 17 adult sheep, with one device placed in each jugular vein. Each implantation was completed in approximately 20 min and did not require any customized tools or techniques. Intravenous glucose tolerance tests (IVGTTs) were performed approximately monthly throughout the studies (30-240 days postimplantation) and mean absolute relative difference (MARD) values were calculated against an Accu-Chek Guide handheld glucometer as the reference standard. The weighted average MARD was 6.84% for all 34 devices during a total of 79 IVGTTs. In addition, no device-related adverse safety events were observed during this long-term in vivo proof-of-concept evaluation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.